Objective: To compare the cost effectiveness of prophylaxiswith a low-molecular-weight heparin with that of prophylaxis withunfractionated heparin for the prevention of venous thromboembolismin ...
Boston, MA - Two new studies comparing the low-molecular-weight heparin (LMWH) enoxaparin (Lovenox® - Aventis) with the new synthetic pentasaccharide fondaparinux (Arixtra® - Sanofi-Synthelabo/Organon ...
Geneva, Switzerland - Low-molecular-weight-heparin (LMWH) prophylaxis in nonsurgical patients at increased risk for venous thromboembolism (VTE) should be extended for about a month after hospital ...
-- EXCLAIM is the First International Study to Show That Extended Thromboprophylaxis Reduces VTE Risk in Acutely-ill Medical Patients With a Statistically Significant 44% Sanofi-aventis announced ...
Please provide your email address to receive an email when new articles are posted on . Until recently, orthopedic surgeons lacked specialty-specific recommendations for preventing venous ...
Examining clinician confidence in the management of breast cancer (BC) based on subtype. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full ...
In total hip or total knee arthroplasty, hypercoagulability typically begins on the operating table and a hypercoagulable state persists for up to 3 months after surgery. For that reason, it is ...
Please provide your email address to receive an email when new articles are posted on . The typical patient undergoing a joint replacement procedure is a woman in her mid-60s with hip pain that causes ...
For patients with a variety of traumatic bone fractures, plain old oral aspirin provided just as good thromboprophylaxis as traditional low-molecular-weight heparin (LMWH) injections in the large ...
Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. Primary prevention with pharmacologic agents (or mechanical methods, if anticoagulants are ...